BioLineRx (BLRX) Cost of Revenue: 2023-2025
Historic Cost of Revenue for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $72,000.
- BioLineRx's Cost of Revenue fell 98.88% to $72,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $11.0 million, marking a year-over-year decrease of 61.63%. This contributed to the annual value of $23.6 million for FY2024, which is 6.59% down from last year.
- Latest data reveals that BioLineRx reported Cost of Revenue of $72,000 as of Q2 2025, which was up 111.76% from $34,000 recorded in Q1 2025.
- BioLineRx's 5-year Cost of Revenue high stood at $8.1 million for Q3 2023, and its period low was $34,000 during Q1 2025.
- In the last 3 years, BioLineRx's Cost of Revenue had a median value of $5.6 million in 2023 and averaged $4.9 million.
- Its Cost of Revenue has fluctuated over the past 5 years, first surged by 63.71% in 2024, then slumped by 99.46% in 2025.
- BioLineRx's Cost of Revenue (Quarterly) stood at $7.7 million in 2023, then tumbled by 30.88% to $5.3 million in 2024, then tumbled by 98.88% to $72,000 in 2025.
- Its Cost of Revenue was $72,000 in Q2 2025, compared to $34,000 in Q1 2025 and $5.3 million in Q4 2024.